Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameInnocare
Stock Code09969
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家處於臨床階段的生物醫藥公司,致力於發現、研發及商業化潛在同類最佳及/或首創的用於治療癌症及自身免疫性疾病的藥物。
Listing Date2020-03-23
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 北京市 昌平區 中關村生命科學園 生命園路8號院8號樓
Business Address (Hong Kong)香港 灣仔 皇后大道東248號 陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.innocarepharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 8.95 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2020-03-11 to 2020-03-16
Global Offering Shares250,324,000 shares
HK Public Offer Shares (Initial)25,034,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)225,290,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,251,617,235 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share50.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,240,399,800

Stock Connect Inclusion Analysis

HK Market Cap HK$ 19.05B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 11,201,974,253
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status亏损人民币554.0百万元
Period-End Cash Balance人民币1876.6百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 1,6171,247
Cost of sales 00
Gross profit 1,6171,247
Other income and gains, net 31,395104,449
Selling and distribution expenses -558-3,458
Administrative expenses -17,523-63,623
Net finance costs -3,441-1,916
Share of associates and JVs -40
Profit before tax -554,023-2,150,351
Income tax expense 00
Profit for the year -554,023-2,150,351
Profit attributable to owners -549,950-2,141,388
Balance Sheet
Item 20182019
Cash and cash equivalents 1,876,6182,291,773
Trade and bills receivables 4437
Total current assets 2,063,5042,408,747
Total current liabilities 72,28965,672
Total equity -838,374-2,947,746
Equity attributable to owners -904,301-3,004,710
Interest-bearing borrowings 1,007,6641,117,176
Cash Flow Statement
Item 201720182019-09
Net cash from operating activities -49,356-17,677
Net cash from investing activities 25,173-888,109
Net cash from financing activities 26,8102,101,300
Net increase in cash 2,6271,195,514
Depreciation of PP&E 5521,0781,080
Depreciation of right-of-use assets 3,1494,2195,039
Amortisation of intangible assets 1791355
Purchase of PP&E -1,417-3,624-10,990
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 9.81
First Day OpenHK$ 9.4
First Day Change9.61%
First Day Volume115988000.0
First Day Turnover1148180000.0
Use of Proceeds
1、預期約1,046.54百萬港元(相當于所得款項凈額的50.0%)將用作為奧布替尼同時在中國及美國正在進行和計劃進行的臨床試驗、準備注冊文件及潛在的商業推出(包括銷售和營銷)提供資金; 2、預期約523.27百萬港元(相當于所得款項凈額的25.0%)將用作為我們的兩個臨床階段候選產品提供資金; 3、預期約313.96百百萬港元(相當于所得款項凈額的15.0%)將用作為我們管線中的六種IND準備階段的候選藥物的研發以及新候選藥物的研發及外部引進提供資金; 4、預期約209.31百萬港元(相當于所得款項凈額的10.0%)將用作我們的營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (6)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 SPDB International Capital Limited CE BFZ375
Joint Lead Managers (6)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 招银国际融资有限公司 CE AVM940 SPDB International Capital Limited CE BFZ375

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Athos Asia Event Driven Master Fund 68,306,400 HKD — 3.05% — 6 months 2020-09-23
2 Golden Valley Global Limited 34,153,200 HKD — 1.52% — 6 months 2020-09-23
3 Hankang Biotech Fund I, L.P. 68,297,450 HKD — 3.05% — 6 months 2020-09-23
4 Matthews Asia Funds 157,108,300 HKD — 7.01% — 6 months 2020-09-23
5 Octagon Investments Master Fund LP 40,991,000 HKD — 1.83% — 6 months 2020-09-23
6 Orient Sun Rise Global Superior Choice SPC 68,297,450 HKD — 3.05% — 6 months 2020-09-23
7 Rock Springs Capital Master Fund LP 68,306,400 HKD — 3.05% — 6 months 2020-09-23
8 Tiger Pacific Master Fund LP 102,459,600 HKD — 4.57% — 6 months 2020-09-23
9 Vivo Funds 170,766,000 HKD — 7.62% — 6 months 2020-09-23
10 WT Investment Management 68,297,450 HKD — 3.05% — 6 months 2020-09-23
11 妙城集团有限公司 34,153,200 HKD — 1.52% — 6 months 2020-09-23
12 中国国有企业结构调整基金股份有限公司 239,063,450 HKD — 10.67% — 6 months 2020-09-23

Directors & Management

PositionChinese nameEnglish Name
Chairman崔霽松—
Company Secretary楊靜文—
No director data available.

Major Shareholders

Major Shareholders & Holdings崔霽松博士及直系家族成員持股約11.38%(上市後),趙仁濱博士及直系家族成員持股約12.43%,TMF (Cayman) Ltd.持股約10.91%,GIC Private Limited持股約9.54%,Vivo Capital VIII, LLC持股約6.80%,LVC實體持股約9.66%,Hebert Pang Kee Chan持股約12.89%。
About this page

This page shows Innocare (09969) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect